Quantcast

Latest Tumors Stories

2014-03-18 08:32:17

Experimental drug designed to fight abdominal cancers passes important test SYDNEY, March 18, 2014 /PRNewswire/ -- Novogen Limited [ASX:NRT; NASDAQ:NVGN] and its joint venture company with Yale University, CanTx Inc, today announced an important milestone with lead candidate drug, Trx-1, demonstrating a potent anti-cancer effect in mice xenografted with human ovarian cancer stem cells. http://photos.prnewswire.com/prnvar/20131220/NY36990LOGO CanTx is seeking a novel approach to...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

Scientists Identify Potent Driver Of Metastasis
2014-03-10 12:44:42

The Wistar Institute Protein Correlates with Breast, Bladder, Melanoma, and Thyroid Tumors An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body. Their study, published in the March issue of the journal Cancer Research, defines the structure of LIMD2 and correlates the protein in metastatic bladder, melanoma, breast, and thyroid tumors....

2014-03-06 13:13:25

Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. Published today in the journal Science Translational...

2014-03-05 11:01:37

Johns Hopkins researchers identify set of genes that can be turned back on and potentially allow for more effective treatment Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment. Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the...

2014-03-05 10:57:36

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Patients who showed responses to the drug, nivolumab (anti-PD-1;...

2014-02-04 11:02:59

Presence of IDH1 mutation determines best treatment for malignant astrocytomas Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years. Now a new study has found that malignant astrocytoma patients whose tumors carry a specific genetic mutation benefit greatly from surgical removal of the largest possible amount of tumor. Preliminary results of the study...

2014-02-03 04:20:02

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood...

2014-01-30 23:03:55

In the second whole-genome sequencing study ever conducted in bladder cancer, a Roswell Park-led team observed two distinct patterns of aberrations, and identified a potential target for therapy. Buffalo, NY (PRWEB) January 30, 2014 In the first whole-genome analysis conducted through the Roswell Park Cancer Institute (RPCI) Center for Personalized Medicine, researchers report that invasive bladder cancers demonstrate two distinct patterns of genetic alteration, one of which may result...

2014-01-30 12:28:43

NEW YORK, Jan. 30, 2014 /PRNewswire-USNewswire/ -- Patients with advanced hepatocellular (or liver) cancer have high mortality rates, with existing drugs demonstrating only a small, but significant survival advantage. By combining a zebrafish model of liver cancer with data from human tumors, researchers from the Icahn School of Medicine at Mount Sinai hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma, the most common...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.